Yunxiao Xu

Yunxiao Xu

Auto-generated profile, based on publicly available information

Yunxiao Xu

Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha 410011, PR China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2013 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
WYWenjuan Yang
Wenjuan Yang
YXYunxiao Xu
Yunxiao Xu

1 May 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YWYewei Wang
Yewei Wang
LFLei Fu
Lei Fu
ASAilian Sun
Ailian Sun
DTDoudou Tang
Doudou Tang
YXYunxiao Xu
Yunxiao Xu
GZGuangsen Zhang
Guangsen Zhang

1 November 2020 in Pathology - Research and Practice
Verified
Journal Article
Closed access
YLYun-Ya Luo
Yun-Ya Luo
ZWZhi-Hua Wang
Zhi-Hua Wang
QYQian Yu
Qian Yu
LYLing-Li Yuan
Ling-Li Yuan
Hongling PengHongling Peng
Hongling Peng
YXYun-Xiao Xu
Yun-Xiao Xu

4 April 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
WYWenzhe Yan
Wenzhe Yan
JLJi Li
Ji Li
YZYang Zhang
Yang Zhang
YYYafei Yin
Yafei Yin
ZCZhao Cheng
Zhao Cheng
GZGuangsen Zhang
Guangsen Zhang
GTF2I-RARA is a newly identified RARA fusion gene in variant acute promyelocytic leukemia (APL) patients with t(7;17)(q11;q21). Clinical manifestation in the patient showed that it is a sort of ATRA-insensitive oncogene and is different from the classic PML-RARA in terms of therapeutic reaction. To reveal the functional characteristics and regulating mechanism of the GTF2I-RARA fusion gene, we established a GTF2I-RARA-transfected HL60 cell model and examined its sensitivity to ATRA by western blot, MTT assay, flow cytometry, and Wright-Giemsa staining. Coimmunoprecipitation and confocal microscopy were used to examine the binding of GTF2I-RARA and transcriptional corepressors. We also performed ChIP-seq to search for potential target genes. Immunoprecipitation, ubiquitination assay, western blot, luciferase assay, and real-time PCR were used to analyze the effects of RNF8 on RARA. Flow cytometry and Wright-Giemsa staining were used to study the effect of MG132 and ATRA on the GTF2I-RARA-transfected HL60 cell model. We confirmed resistance of GTF2I-RARA to ATRA. Compared with PML-RARA, GTF2I-RARA has a higher affinity to HDAC3 under ATRA treatment. Using the ChIP-sequencing approach, we identified 221 GTF2I-RARA binding sites in model cells and found that the RING finger protein 8 (RNF8) is a target gene of GTF2I-RARA. RNF8 participates in disease progression and therapy resistance in APL with the GTF2I-RARA transcript. Elevated RNF8 expression promotes the interaction between RARA and RNF8 and induces RARA Lys-48 linkage ubiquitylation and degradation, resulting in attenuated transcriptional activation of RARA. Our results suggest that RNF8 is a key GTF2I-RARA downstream event. Using the combination of MG132 and ATRA to treat GTF2I-RARA-HL60 cells, a synergistic effect leading to GTF2I-RARA-HL60 cell differentiation was confirmed. Taken together, the targeting of RNF8 may be an alternative choice for treatment in variant APL with GTF2I-RARA fusion.